Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

IRVINE, Calif. – Botox maker Allergan is rejecting a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited $46 billion offer undervalues the company and carries significant risk.
Shortly after Canada’s Valeant and activist investor Bill Ackman made their offer public last month, Valeant announced a so-called poison pill plan, a defensive tactic that makes a buyout prohibitively expensive.
Valeant and Ackman offered to exchange each Allergan share for $48.30 in cash and a portion of shares of Valeant Pharmaceuticals International Inc.
Allergan stockholders would own 43 per cent of the combined company under that proposal. Allergan Inc. says Valeant’s uncertain long-term growth prospects and business model create a risk for Allergan shareholders.
Allergan Inc., based in Irvine, has long been considered one of the star performers in the specialty pharmaceutical sector.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.